
Drugs giant AstraZeneca has revealed plans to overhaul its US listing, but stressed it will keep its headquarters in the UK and remain on the London market.
Cambridge-based AstraZeneca is set to directly list its ordinary shares on the New York Stock Exchange (NYSE) from February next year in a move designed to help the group “reach a broader mix of global investors”.